Page 21 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY

43. Bernink JH, Germar K, Spits H. The role of ILC2 in pathology of type 2 in ammatory diseases. Curr Opin Immunol 2014; 31:115-20.
44. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway in amma on in nonallergic asthma. Nat Med 2013; 19:977-9.
45. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribu on of sputum cellular phenotype in a large asthma cohort: predic ng factors for eosinophilic vs neutrophilic in amma on. Bmc Pulmonary Medicine 2013; 13.
46. Vroman H, van den Blink B, Kool M. Mode of dendri c cell ac va on: the decisive hand in Th2/Th17 cell di eren a on. Implica ons in asthma severity? Immunobiology 2015; 220:254-61.
47. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, et al. TH2 and TH17 in ammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015; 7:301ra129.
48. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerba ons and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
49. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocor coid-sparing e ect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189-97.
50. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455-66.
51. Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count >= 3% in a cohort of unselected pa ents with asthma. Thorax 2010; 65:1039-44.
52. Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentra on to iden fy eosinophilic airway in amma on: an observa onal study in adults with asthma. Clinical and Experimental Allergy 2005; 35:1175-9.
53. Chung KF. Targe ng the interleukin pathway in the treatment of asthma. Lancet 2015; 386:1086-96.
GENERAL INTRODUCTION AND AIMS
19